Small Molecule Angiotensin II Type 2 Receptor (AT2R) Antagonists as Novel Analgesics for Neuropathic Pain: Comparative Pharmacokinetics, Radioligand Binding, and Efficacy in Rats

Pain Medicine (United States)

Volumn 14, Issue 5, 2013, Pages 692-705

  Smith, Maree T ^a,b   Wyse, Bruce D ^a,b   Edwards, Stephen R ^a,b  

^a Ctr for Drug Design and Development   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Analgesia; Neuropathic Pain; Oral Bioavailability; Pharmacokinetics; Radioligand Binding

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; EMA 200; EMA 300; EMA 400; EMA 401; RADIOLIGAND; SARALASIN; UNCLASSIFIED DRUG;

ALLODYNIA; ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; BOLUS INJECTION; CHROMATOGRAPHY; CHRONIC DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; ENANTIOMER; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MALE; NERVE LIGATION; NEUROPATHIC PAIN; NONHUMAN; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; RAT; SCIATIC NERVE INJURY; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY;

EID: 84878209953     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12063     Document Type: Article

References (24)

1. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010;150:573-581.
2. Martin YB, Herradon G, Ezquerra L. Uncovering new pharmacological targets to treat neuropathic pain by understanding how the organism reacts to nerve injury. Curr Pharm Des 2011;17:434-448.
3. Burgess G, Williams D. The discovery and development of analgesics: New mechanisms, new modalities. J Clin Invest 2010;120:3753-3759.
4. Yu L, Shao C, Gao L. Developmental expression patterns for angiotensin receptors in mouse skin and brain. J Renin Angiotensin Aldosterone Syst 2012; [Epub ahead of print]; doi: 10.1177/1470320312467557.
5. Kang J, Sumners C, Posner P. Modulation of net outward current in cultured neurons by angiotensin II: Involvement of AT1 and AT2 receptors. Brain Res 1992;580:317-324.
6. Gendron L, Payet MD, Gallo-Payet N. Signals from the AT2 (angiotensin type 2) receptor of antiotensin II inhibit p21ras and activate MAPK (mitogen-activated protein kinase) to induce morphological neuronal differentiation in NG108-15 cells. Mol Endocrinol 1999;13:1615-1626.
7. Plouffe B, Guimond MO, Beaudry H, Gallo-Payet N. Role of tyrosine kinase receptors in angiotensin II AT2 receptor signaling: Involvement in neurite outgrowth and in p42/p44mapk activation in NG108-15 cells. Endocrinology 2006;147:4646-4654.
8. Stroth U, Blume A, Mielke K, Unger T. Angiotensin AT(2) receptor stimulates ERK1 and ERK2 in quiescent but inhibits ERK in NGF-stimulated PC12W cells. Brain Res Mol Brain Res 2000;78:175-180.
9. Chakrabarty A, Blacklock A, Svojanovsky S, Smith PG. Estrogen elicits dorsal root ganglion axon sprouting via a renin-angiotensin system. Endocrinology 2008;149:3452-3460.
10. Li C, Liu B, Chang J, etal. A modern in vivo pharmacokinetic paradigm: Combining snapshot, rapid and full PK approaches to optimize and expedite early drug discovery. Drug Discov Today 2013;18:71-78.
11. Bergsma DJ, Ellis C, Kumar C, etal. Cloning and characterization of a human angiotensin II type 1 receptor. Biochem Biophys Res Commun 1992;183:989-995.
12. Tsuzuki S, Ichiki T, Hakakubo H, etal. Molecular cloning and expression of the gene encoding human angiotensin II type 2 receptor. Biochem Biophys Res Commun 1994;200:1449-1454.
13. Cerep. In vitro pharmacology: Human AT1 and AT2 receptor binding assays-Study of EMA401 and EMA402. 2006; Study Number: 11781.
14. Cerep. In vivo rat pharmacokinetics: Study of EMA400. 2006; Study Number: 11744.
15. MPI Research, Inc. A bioavailability study of EMA401.Na in rats. 2007; Study Number: 1452-008.
16. Bennett GJ, Xie YK. A peripheral mononeuropathy in the rat that produces disorders of pain sensation like those seen in man. Pain 1988;33:87-107.
17. Microconstants. Method for the determination of EMA401 in rat plasma using high-performance liquid chromatography with mass spectrometric (MS/MS) detection. 2007; Method Number: MN7080.
18. Gibaldi M. Biopharmaceutics and Clinical Pharmacokinetics. Philadelphia, PA: Lea and Febiger; 1984.
19. Blankley CJ, Hodges JC, Klutchko SR, etal. Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 subtype. J Med Chem 1991;34:3248-3260.
20. Klutchko S, Hamby JM, Hodges JC. Tetrahydroisoquinoline derivatives with AT2-specific angiotensin II receptor binding inhibitory activity. Bioorg Med Chem Lett 1994;4:57-62.
21. Bosnyak S, Jones ES, Christopoulos A, etal. Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin Sci (Lond) 2011;121:297-303.
22. Yoshitani T, Yagi H, Inotsume N, Yasuhara M. Effect of experimental renal failure on the pharmacokinetics of losartan in rats. Biol Pharm Bull 2002;25:1077-1083.
23. Ripley E, Hirsch A. Fifteen years of losartan: What have we learned about losartan that can benefit chronic kidney disease patients? Int J Nephrol Renovasc 2010;3:93-98.
24. Porello ER, Delbridge LM, Thomas WG. The angiotensin II type 2 (AT2) receptor: An enigmatic seven transmembrane receptor. Front Biosci 2009;14:958-972.